U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H17Cl3N2O2.HNO3
Molecular Weight 486.733
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of OMOCONAZOLE NITRATE

SMILES

O[N+]([O-])=O.C\C(N1C=CN=C1)=C(\OCCOC2=CC=C(Cl)C=C2)C3=CC=C(Cl)C=C3Cl

InChI

InChIKey=BNDOPUYTWJQTOE-VSOKSMTPSA-N
InChI=1S/C20H17Cl3N2O2.HNO3/c1-14(25-9-8-24-13-25)20(18-7-4-16(22)12-19(18)23)27-11-10-26-17-5-2-15(21)3-6-17;2-1(3)4/h2-9,12-13H,10-11H2,1H3;(H,2,3,4)/b20-14-;

HIDE SMILES / InChI
Molecular Formula HNO3
Molecular Weight 63.0128
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C20H17Cl3N2O2
Molecular Weight 423.72
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description

Omoconazole is an azole antifungal drug, is used to treat candidiasis; dermatophytes and Pityriasis Versicolor

Approval Year

Unknown
149124
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
Unknown

Approved Use

Unknown
Curative
Approved
8583
Unknown

Approved Use

Unknown
Curative
Approved
8583
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
1 % single, topical
Studied dose
Dose: 1 %
Route: topical
Route: single
Dose: 1 %
Sources:
https://pubmed.ncbi.nlm.nih.gov/3393168/
healthy
Health Status: healthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3393168/
Sources:
https://pubmed.ncbi.nlm.nih.gov/3393168/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252
inhibitor
2438
inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2C19
2057

CYP1A2
2153
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
2633
 yes [IC50 0.1738 uM]
CYP2C9
2497
 yes [IC50 0.5495 uM]
CYP2C19
2141
 yes [IC50 0.7762 uM]
CYP2D6
2546
 yes [IC50 0.8709 uM]
CYP1A2
2333
 yes [IC50 2.2877 uM]
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
PubMed

PubMed

TitleDatePubMed
Ultrastructural alterations of Candida albicans induced by a new imidazole antimycotic omoconazole nitrate.
1997
Patents

Patents

JP2011528275A
456

Sample Use Guides

In Vivo Use Guide
Cream; Topical; Omoconazole Nitrate 1%
Route of Administration: Topical
In Vitro Use Guide
The treatment of growing Candida cultures with fungistatic doses (0.4 to 4 micrograms/ml) of omoconazole nitrate (OMZ) produced the formation of a chain or cluster of cells. Thickening of the cell wall and accumulation of electrondense vesicles in the wall were clearly observed
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:06:25 GMT 2025
Edited
by admin
on Mon Mar 31 18:06:25 GMT 2025
Record UNII
15LTY5STY6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OMOCONAZOLE NITRATE
JAN   MART.   MI   USAN   WHO-DD  
USAN  
Official Name English
10 80 07
Preferred Name English
OMOCONAZOLE NITRATE [JAN]
Common Name English
Omoconazole nitrate [WHO-DD]
Common Name English
OMOCONAZOLE NITRATE [MI]
Common Name English
(Z)-1-(2,4-DICHLORO-.BETA.-(2-(P-CHLOROPHENOXY)ETHOXY)-.ALPHA.-METHYLSTYRYL)IMIDAZOLE MONONITRATE
Common Name English
1H-IMIDAZOLE, 1-(2-(2-(4-CHLOROPHENOXY)ETHOXY)-2-(2,4-DICHLOROPHENYL)-1-METHYLETHENYL)-, (Z)-, MONONITRATE
Common Name English
OMOCONAZOLE MONONITRATE
Common Name English
OMOCONAZOLE NITRATE [MART.]
Common Name English
OMOCONAZOLE NITRATE [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C514
Created by admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
Code System Code Type Description
EVMPD
SUB03516MIG
Created by admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
PRIMARY
NCI_THESAURUS
C75202
Created by admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
PRIMARY
MERCK INDEX
m8211
Created by admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
PRIMARY Merck Index
USAN
II-50
Created by admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
PRIMARY
PUBCHEM
3036590
Created by admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
PRIMARY
FDA UNII
15LTY5STY6
Created by admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
PRIMARY
RXCUI
134933
Created by admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
PRIMARY RxNorm
CAS
83621-06-1
Created by admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
PRIMARY
SMS_ID
100000085938
Created by admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
PRIMARY
ChEMBL
CHEMBL2046550
Created by admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
PRIMARY
MESH
C050566
Created by admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
PRIMARY
Related Record Type Details
Structure of OMOCONAZOLE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of OMOCONAZOLE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966